-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical Network, March 15 News On March 11, the official website of NMPA showed that Xintai Pharmaceutical's Oxiracetam injection was approved for listing.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is an analogue of piracetam, which can improve the memory and learning function of patients with senile dementia and memory disorders.
It is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
It is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
According to Meinenet data, in recent years , the terminal sales of Oxiracetam injection in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have continued to decline, from 8 billion in 2016.
The yuan fell to 5.
19 billion yuan in 2019.
The yuan fell to 5.
19 billion yuan in 2019.
Sales of Oxiracetam Terminals in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, Oxiracetam products marketed in China involve three dosage forms: injections, capsules and tablets.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
Oxiracetam injection listing application enterprise under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The manufacturer of Oxiracetam tablets only has North China Pharmaceutical, and there are 2 manufacturers of Oxiracetam capsules and Oxiracetam for injection.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
Source: Mi Neiwang database, NMPA
Medical Network, March 15 News On March 11, the official website of NMPA showed that Xintai Pharmaceutical's Oxiracetam injection was approved for listing.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is an analogue of piracetam, which can improve the memory and learning function of patients with senile dementia and memory disorders.
It is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
It is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
According to Meinenet data, in recent years , the terminal sales of Oxiracetam injection in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have continued to decline, from 8 billion in 2016.
The yuan fell to 5.
19 billion yuan in 2019.
The yuan fell to 5.
19 billion yuan in 2019.
Sales of Oxiracetam Terminals in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, Oxiracetam products marketed in China involve three dosage forms: injections, capsules and tablets.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
Oxiracetam injection listing application enterprise under review
Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The manufacturer of Oxiracetam tablets only has North China Pharmaceutical, and there are 2 manufacturers of Oxiracetam capsules and Oxiracetam for injection.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
Source: Mi Neiwang database, NMPA
Medical Network, March 15 News On March 11, the official website of NMPA showed that Xintai Pharmaceutical's Oxiracetam injection was approved for listing.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is the first batch of key drugs to be monitored.
According to data from Meinenet, the terminal sales of Oxiracetam in China's public medical institutions have continued to decline in recent years, from 8 billion yuan in 2016 to 5.
19 billion yuan in 2019.
Oxiracetam injection is an analogue of piracetam, which can improve the memory and learning function of patients with senile dementia and memory disorders.
It is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
Medicine, medicine, medicineIt is suitable for brain injury and its caused neurological deficit, memory and intellectual impairment.
treatment.
In July 2019, Oxiracetam was included in the first batch of national key monitoring drugs list.
According to Meinenet data, in recent years , the terminal sales of Oxiracetam injection in Chinese urban public hospitals , county-level public hospitals, urban community centers, and township health centers (Chinese public medical institutions) have continued to decline, from 8 billion in 2016.
The yuan fell to 5.
19 billion yuan in 2019.
Hospital hospital hospitalThe yuan fell to 5.
19 billion yuan in 2019.
Sales of Oxiracetam Terminals in Public Medical Institutions in China
Source: Mi Nei.
com, China's public medical institutions terminal competition pattern
com, China's public medical institutions terminal competition pattern
At present, Oxiracetam products marketed in China involve three dosage forms: injections, capsules and tablets.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
In 2020H1, the sales of Oxiracetam in China's public medical institutions exceeded 1 billion yuan, a year-on-year decline of 57.
59%.
Among them, injections accounted for 85.
1% of the market share, and capsules accounted for 14.
9%.
Oxiracetam injection listing application enterprise under review
Enterprise business enterprise Source: Meinenet MED2.
0 Chinese Drug Evaluation Database
0 Chinese Drug Evaluation Database
The manufacturer of Oxiracetam tablets only has North China Pharmaceutical, and there are 2 manufacturers of Oxiracetam capsules and Oxiracetam for injection.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
With the approval of Xintai Pharmaceutical's Oxiracetam injection, there are 13 manufacturers of this product.
In addition, Oxiracetam injection has 7 companies whose listing applications are under review, including Zhengda Fenghai, Warner Pharmaceuticals, Sihuan Pharmaceutical, etc.
Source: Mi Neiwang database, NMPA
